| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8501818 | HELSINN | Stabilized compositions of alkylating agents and methods of using same |
Mar, 2026
(1 year, 10 months from now) | |
| US8501819 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(1 year, 10 months from now) | |
| US8450375 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(1 year, 10 months from now) | |
| US7838564 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(1 year, 10 months from now) | |
| US9382191 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(1 year, 10 months from now) | |
| US7872050 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Jul, 2029
(5 years from now) | |
Valchlor is owned by Helsinn.
Valchlor contains Mechlorethamine Hydrochloride.
Valchlor has a total of 6 drug patents out of which 0 drug patents have expired.
Valchlor was authorised for market use on 23 August, 2013.
Valchlor is available in gel;topical dosage forms.
Valchlor can be used as alkylating drug indicated for the topical treatment of stage ia and ib mycosis fungoides-type cutaneous t-cell lymphoma in patients who have received prior skin directed therapy.
The generics of Valchlor are possible to be released after 08 July, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Aug 23, 2020 |
| New Dosage Form(NDF) | Aug 23, 2016 |
| Orphan Drug Exclusivity(ODE-51) | Aug 23, 2020 |
Drugs and Companies using MECHLORETHAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 August, 2013
Treatment: Alkylating drug indicated for the topical treatment of stage ia and ib mycosis fungoides-type cutaneous t-cell lymphoma in patients who have received prior skin directed therapy
Dosage: GEL;TOPICAL
VALCHLOR family patents
